

Phase III MDD Trial

Study Basics

Disease: Major Depressive Disorder

— Phase: 3

Target geography: United States

Total number of sites: 53

Background

The sponsor was facing an increasingly tight timeline for a U.S. based Major Depressive Disorder trial and experiencing start up delays across their sites. They partnered with Inato to develop a solution for combating the limited time frame and achieving their goals across activation and enrollment.



The Problem

The sponsor was encountering delays as a result of slow enrollment and complications with the digital requirements of the study. Site selection was made difficult as the sponsor and CRO sought out sites with the capacity to navigate the remote nature of the trial and overall, they were looking to accelerate their timelines. Additionally, the sponsor was interested in playing a more collaborative role in the recruitment and selection process. They turned to Inato based on previous experience quickening trial activations and their close relationships with sites.



On average, compared to non-Inato sites, Inato sites activated

16.5 WEEKS FASTER



4 WEEKS FASTER THAN SITES SELECTED AT THE SAME TIME

Average days between selection and activation

158.3 NON-INATO SITES

43
INATO SITES

The Solution

With existing results from other Inato trials validating the capabilities of community-based sites, Inato identified a strategy to accelerate activation under the tight study timelines. Inato's project manager developed an approach that consisted of highly involved written and verbal communication with the CRO and sponsor.

Inato's project manager built a collaborative activation tool designed to assign and monitor expected timelines, tasks, and owners related to selection and activation.

The sponsor, CRO, and Inato all updated the tool when actions were completed, enabling transparency into the rapid progress sites were making.

Throughout the activation process, Inato provided real time progress reports for the sponsor and CRO and offered consistent support for the sites to meet their goals. Inato scheduled weekly meetings with the CRO to go through individual site progress and supply the sponsors with up to date information on the sites. This continual transparency permitted steady communication between all involved parties and the ability to address and resolve any miscommunications that arose through the duration of the activation stage.

Ultimately, the streamlined initiative led to the Inato sites outperforming the non-Inato sites in the trial.

Not only did this strategy enable Inato sites to activate quicker as compared to non-Inato sites in this trial, these sites also activated faster than other sites in previous Inato trials. The Inato team working on this study delivered the commitment and support the sponsor was looking for to achieve fast activation in their Major Depressive Disorder trial.